<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818502</url>
  </required_header>
  <id_info>
    <org_study_id>ABT-CIP-10313</org_study_id>
    <nct_id>NCT04818502</nct_id>
  </id_info>
  <brief_title>Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation</brief_title>
  <acronym>RESOLVE-MR</acronym>
  <official_title>Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation (RESOLVE-MR) (Tendyne™ PMCF Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and performance of the Tendyne™ Mitral Valve System when used as&#xD;
      intended in a contemporary, real-world setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Tendyne RESOLVE-MR study (Real World Study of the Tendyne™ Mitral Valve System to Treat&#xD;
      Mitral Regurgitation) is a prospective, single arm, multi-center, PMCF study, which will be&#xD;
      used to support the CE Mark requirement of monitoring safety and performance for any&#xD;
      complications or issues arising in a post-market setting.&#xD;
&#xD;
      The objective of the Tendyne RESOLVE-MR study is to confirm the safety and performance of the&#xD;
      Tendyne Mitral Valve System in patients with symptomatic, moderate-to-severe or severe mitral&#xD;
      regurgitation (MR) who are considered by the local heart team as eligible for a transapical&#xD;
      transcatheter mitral valve implantation in a real-world setting. This clinical study is&#xD;
      intended to satisfy post-market clinical follow-up requirements of CE Mark.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint for MR Elimination at 1 Year</measure>
    <time_frame>At 1 year</time_frame>
    <description>The primary endpoint MR Elimination will be assessed at one year post-procedure and is defined as original Tendyne valve remains implanted, free from surgical removal/replacement or transcatheter mitral valve implantation (valve-in-valve), and MR &lt; Grade I (mild, measured by Echocardiographic Core Lab)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure Safety (PS)</measure>
    <time_frame>Day 0, at exit procedure room</time_frame>
    <description>This will be assessed at exit from the procedure room and is defined as freedom from procedural mortality, unplanned surgical or interventional procedures related to the Tendyne valve or access procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from LVOT Obstruction (LVOTO) at 30 Days</measure>
    <time_frame>At Day 30</time_frame>
    <description>This will be assessed at 30 days post-procedure and is defined as mean LVOT gradient increase &lt;10 mmHg from baseline (measured by the Echo Core Lab), and free of unplanned intervention for LVOTO.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Paravalvular Leak (PVL) at 30 Days</measure>
    <time_frame>At Day 30</time_frame>
    <description>This will be assessed at 30 days post-procedure and is defined as the Tendyne prosthesis PVL ≤ mild (Grade I), as measured by the Echo Core Lab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricle Reverse Remodeling at 1 Year</measure>
    <time_frame>At 1 Year</time_frame>
    <description>This will be assessed at 1-year post-procedure and is defined as the proportion of survivors at one year with baseline Left Ventricle End Diastolic Volume Index (LVEDVi) &gt; 96ml/m2 that experience 10% or greater reduction in LVEDVi at one year (assessed by the Echo Core lab).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-Cause Mortality at 30 Days</measure>
    <time_frame>At Day 30</time_frame>
    <description>This will be assessed at 30 days post-procedure and is defined as the proportion of subjects who die within 30 days post-procedure for any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Device Durability (LDD) at 5 Years</measure>
    <time_frame>At 5 Years</time_frame>
    <description>This will be assessed at 5 years post-procedure and is defined as original Tendyne device remains implanted, free from surgical removal/replacement or transcatheter mitral valve implantation (valve-in-valve), and free from Structural Valve Dysfunction</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tendyne™ Mitral Valve System</intervention_name>
    <description>Transcatheter mitral valve implantation (TMVI) using the Tendyne™ Mitral Valve System , in which a bioprosthetic valve is implanted within the native mitral valve.</description>
    <other_name>Transcatheter Mitral Valve Implantation (TMVI)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects of all genders from the population of patients meeting indications for a Tendyne&#xD;
        implant as stated within the IFU. Subjects must meet all eligibility criteria and provide&#xD;
        written informed consent.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is indicated for the Tendyne Mitral Valve System per the Instructions for Use.&#xD;
&#xD;
          2. Patient is willing and able to comply with all follow-up requirements through five&#xD;
             years, including study-required testing, medications, and attending all follow-up&#xD;
             visits.&#xD;
&#xD;
          3. Patient provides written informed consent prior to any study-specific procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is in another clinical study that may impact the follow-up or results of this&#xD;
             study.&#xD;
&#xD;
          2. Patient is pregnant or nursing or plan to become pregnant during the study follow-up&#xD;
             period.&#xD;
&#xD;
          3. Patient is under the age of 18 or age of legal consent.&#xD;
&#xD;
          4. Patient has other anatomic or comorbid conditions, or other medical, social, or&#xD;
             psychological conditions that, in the investigator's opinion, may limit the subject's&#xD;
             ability to participate in the clinical study or to comply with follow-up requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Bart Janssens</last_name>
    <phone>+32471723201</phone>
    <email>bart.janssens@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karine Miquel</last_name>
    <phone>+32479600107</phone>
    <email>karine.miquel@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kepler University Hospital</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Zierer</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Zierer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Louis Labrousse</last_name>
    </contact>
    <investigator>
      <last_name>Louis Labrousse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erwan Donal</last_name>
    </contact>
    <investigator>
      <last_name>Erwan Donal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas Dumonteil</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas Dumonteil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart and Diabetes Center NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sabine Bleiziffer</last_name>
    </contact>
    <investigator>
      <last_name>Sabine Bleiziffer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Heart Center Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joerg Kempfert</last_name>
    </contact>
    <investigator>
      <last_name>Joerg Kempfert</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg Nickenig</last_name>
    </contact>
    <investigator>
      <last_name>Georg Nickenig</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Walther</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Walther</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Heart Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lenard Conradi</last_name>
    </contact>
    <investigator>
      <last_name>Lenard Conradi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsclinic Cologne</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan Baldus</last_name>
    </contact>
    <investigator>
      <last_name>Stephan Baldus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>German Heart Center Munich</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hendrik Ruge</last_name>
    </contact>
    <investigator>
      <last_name>Hendrik Ruge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-Universität (LMU) München / Campus Großhadern</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joerg Hausleiter</last_name>
    </contact>
    <investigator>
      <last_name>Joerg Hausleiter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancisi Cardiovascular Center - Politechnic University of Marcher</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Di Eusanio</last_name>
    </contact>
    <investigator>
      <last_name>Marco Di Eusanio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Sonia Petronio</last_name>
    </contact>
    <investigator>
      <last_name>Anna Sonia Petronio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUMC+</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peyman Sardari Nia</last_name>
    </contact>
    <investigator>
      <last_name>Peyman Sardari Nia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gry Dahle</last_name>
    </contact>
    <investigator>
      <last_name>Gry Dahle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel, Clinic for Cardiac Surgery</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oliver Reuthebuch</last_name>
    </contact>
    <investigator>
      <last_name>Oliver Reuthebuch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Insel Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabien Praz</last_name>
    </contact>
    <investigator>
      <last_name>Fabien Praz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tendyne</keyword>
  <keyword>Tendyne Mitral Valve System</keyword>
  <keyword>Transcatheter</keyword>
  <keyword>Mitral Regurgitation</keyword>
  <keyword>Heart Valve disease</keyword>
  <keyword>Mitral Valve Regurgitation</keyword>
  <keyword>Mitral Insufficiency</keyword>
  <keyword>Transcatheter intervention</keyword>
  <keyword>Transcatheter Mitral Valve Implantation</keyword>
  <keyword>Transcatheter Mitral Valve Replacement</keyword>
  <keyword>Transapical Transcatheter Mitral Valve Implantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

